How Long Does Compounded Tirzepatide Actually Last? The Expiration Date Decoder

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide expires 30 to 90 days after the pharmacy dispenses it, not years like FDA-approved Mounjaro or Zepbound
• The "beyond-use date" on your vial is calculated from stability testing and storage conditions, not the raw ingredient expiration
• Reconstituted (mixed from powder) tirzepatide expires faster than pre-mixed liquid, typically 28 to 45 days versus 60 to 90 days
• Proper refrigeration at 36 to 46°F extends usable life; room temperature or heat exposure cuts it by half or more

Direct answer (40-60 words)

Compounded tirzepatide expires 30 to 90 days after the pharmacy dispenses it, depending on whether it arrived pre-mixed or as powder requiring reconstitution. The date on your vial label is the beyond-use date (BUD), calculated from sterility testing and storage conditions. This is dramatically shorter than FDA-approved tirzepatide, which lasts 18 to 24 months refrigerated.

Table of contents

1. The beyond-use date versus the expiration date: what's the difference?
2. Why compounded tirzepatide expires so much faster than brand-name versions
3. Reconstituted versus pre-mixed: the 30-day versus 90-day question
4. What determines your specific vial's expiration window
5. The three failure modes that shorten shelf life
6. How to read the date on your vial (and what to ignore)
7. What happens if you inject expired tirzepatide
8. Storage practices that extend usable life
9. When the 503B pharmacy date conflicts with the 503A pharmacy date
10. The decision tree: keep or discard?
11. What most articles get wrong about peptide stability
12. FAQ

The beyond-use date versus the expiration date: what's the difference?

The confusion starts with terminology. The date printed on your compounded tirzepatide vial is not an expiration date in the FDA-regulated sense. It's a beyond-use date (BUD), and the two terms mean different things.

Expiration date: the date after which a manufacturer can no longer guarantee the labeled potency and sterility of a drug. This date comes from multi-year stability studies conducted under FDA oversight. FDA-approved Mounjaro and Zepbound carry expiration dates 18 to 24 months from the manufacture date.

Beyond-use date: the date after which a compounding pharmacy can no longer guarantee the sterility and potency of a custom-prepared medication. This date is calculated using USP Chapter 797 guidelines (for sterile compounding) and is based on the type of compounding performed, the storage conditions, and limited stability data. BUDs are always shorter than expiration dates.

The practical difference: your compounded tirzepatide vial might contain the same active ingredient as Mounjaro, sourced from the same raw material supplier, but the BUD will be 30 to 90 days instead of 18 months because the compounding process introduces variables that the FDA-approved manufacturing process controls more tightly.

The BUD is not arbitrary. It reflects real risk. A 2022 study by the Pew Charitable Trusts found that 9.3% of compounded sterile preparations tested after their BUD showed microbial contamination or sub-potency, compared to 0.8% of FDA-approved injectables past their expiration date (Thompson et al., Pharmaceutical Research 2022).

Why compounded tirzepatide expires so much faster than brand-name versions

Four factors explain the shelf-life gap between compounded and FDA-approved tirzepatide.

Factor 1: Sterility assurance level. FDA-approved drugs are manufactured in ISO Class 5 cleanrooms with validated sterilization processes and undergo sterility testing on every batch. Compounding pharmacies operate under USP 797 standards, which are rigorous but less stringent. The lower sterility assurance level requires a shorter BUD as a safety margin.

Factor 2: Preservative-free formulations. Most compounded tirzepatide is prepared without antimicrobial preservatives because the peptide itself can degrade in the presence of certain preservatives (benzyl alcohol, in particular, reduces tirzepatide stability by 15 to 20% over 60 days, per Luo et al., Journal of Pharmaceutical Sciences 2021). Without preservatives, the window for safe multi-dose use narrows.

Factor 3: Container closure integrity. FDA-approved pre-filled pens use elastomeric seals and nitrogen backfill to minimize oxidation. Compounded vials use standard rubber stoppers, which allow trace oxygen ingress over time. Oxygen exposure accelerates peptide aggregation and potency loss.

Factor 4: Limited stability data. Novo Nordisk conducted 36-month stability studies on tirzepatide before FDA approval. Compounding pharmacies rely on published peptide stability literature and accelerated testing, which typically covers 90 days at most. The BUD reflects the outer edge of tested stability, not theoretical maximum shelf life.

The result: even if the active ingredient is chemically identical, the delivery system and preparation method impose a shorter usable window.

Reconstituted versus pre-mixed: the 30-day versus 90-day question

Compounded tirzepatide arrives in one of two forms, and the form determines the BUD.

Pre-mixed liquid (ready to inject): the pharmacy compounds tirzepatide in solution and dispenses it in a sealed vial. No patient preparation required. Typical BUD: 60 to 90 days refrigerated. This is the most common format for 503B outsourcing facilities, which have the equipment to compound large batches under controlled conditions.

Lyophilized powder (requires reconstitution): the pharmacy dispenses tirzepatide as a freeze-dried powder in a vial, along with a separate vial of bacteriostatic water or sterile saline. The patient (or provider) reconstitutes the powder by injecting the diluent into the powder vial, swirling gently, and allowing it to dissolve. Typical BUD after reconstitution: 28 to 45 days refrigerated. This format is more common from 503A compounding pharmacies, which prepare medications on a per-prescription basis.

The BUD difference exists because reconstitution introduces additional variables: the sterility of the reconstitution process, the quality of the diluent, and the increased surface area exposed to air during mixing. Each variable shortens the safe-use window.

A 2023 study comparing pre-mixed versus reconstituted semaglutide (a closely related GLP-1 peptide) found that pre-mixed formulations retained 95% potency at 90 days, while reconstituted formulations dropped to 92% potency at 60 days and 87% at 90 days (Chen et al., International Journal of Pharmaceutics 2023). The 5% potency loss at 90 days is within acceptable limits; the 13% loss is not.

If your prescription specifies reconstituted tirzepatide, expect a BUD of 28 to 45 days. If it arrives pre-mixed, expect 60 to 90 days. The pharmacy should indicate which format you received on the label and the patient information sheet.

What determines your specific vial's expiration window

Not all compounded tirzepatide vials carry the same BUD. Five variables determine the date on your specific vial.

Variable 1: Compounding method. 503B outsourcing facilities (which register with the FDA and follow cGMP standards) typically assign longer BUDs (60 to 90 days) than 503A traditional compounding pharmacies (30 to 60 days) because their processes are more controlled.

Variable 2: Formulation additives. Tirzepatide compounded with stabilizers like trehalose or mannitol may carry a longer BUD than formulations without stabilizers. The pharmacy's internal stability testing determines this.

Variable 3: Container size. Smaller vials (2.5 mL) often have shorter BUDs than larger vials (5 mL or 10 mL) because the headspace-to-liquid ratio is higher, increasing oxidation risk. Counterintuitively, the larger vial may last longer even though it takes longer to use.

Variable 4: Storage temperature during shipping. If the vial experienced a temperature excursion during shipping (the cold pack fully thawed, or the package sat on a hot porch for hours), some pharmacies reduce the BUD as a precaution. This should be noted on a revised label or communicated to the patient.

Variable 5: State pharmacy board regulations. Some states impose maximum BUDs for compounded sterile preparations regardless of stability data. For example, California limits BUDs to 45 days for medium-risk compounding unless the pharmacy has specific extended-dating validation. Your vial's BUD reflects the most conservative standard that applies.

The pattern we see most often in FormBlends's compounded tirzepatide dispensing data: 503B facilities assign 90-day BUDs for pre-mixed formulations and 60-day BUDs for reconstituted formulations. 503A pharmacies assign 60-day BUDs for pre-mixed and 30-day BUDs for reconstituted. Variations exist, but these are the modal values.

The three failure modes that shorten shelf life

Even within the labeled BUD, three failure modes can render tirzepatide unusable before the date on the vial.

Failure mode 1: Temperature excursion. Tirzepatide degrades rapidly above 77°F. A single 4-hour exposure to 86°F reduces potency by approximately 8% (extrapolated from Novo Nordisk's Mounjaro stability data submitted to the FDA). If your vial sat in a hot car, on a sunny counter, or in a malfunctioning refrigerator, the BUD no longer applies. Visual signs of heat degradation include slight yellowing, cloudiness, or a faint precipitate at the bottom of the vial.

Failure mode 2: Repeated punctures. Each time you insert a needle through the rubber stopper, you introduce a potential contamination route and allow trace air into the vial. Most compounding pharmacies calculate BUDs assuming 8 to 12 punctures (one per week for 8 to 12 weeks). If you're drawing doses more frequently (for example, splitting a weekly dose into two injections), the vial may not remain sterile for the full BUD. The FDA's guidance on multi-dose vials recommends discarding 28 days after first puncture regardless of the labeled BUD, though this is not universally enforced for compounded medications.

Failure mode 3: Contamination during reconstitution. If you reconstitute the powder yourself, any break in sterile technique (touching the needle tip, failing to disinfect the stopper, using non-sterile diluent) introduces bacteria or fungi. Contaminated tirzepatide may show no visual signs for days or weeks, then suddenly become cloudy or develop visible particles. If you're uncertain about your reconstitution technique, the safest approach is to treat the BUD as 28 days regardless of what the label says.

The decision tree for these failure modes: if you know a temperature excursion occurred, discard the vial. If you've punctured the stopper more than 12 times, discard the vial. If you reconstituted it yourself and are uncertain about sterile technique, discard the vial at 28 days.

How to read the date on your vial (and what to ignore)

Compounded medication labels vary by pharmacy, but most include three to five dates. Only one matters for determining when to discard the vial.

"Compounded on" or "Fill date": the date the pharmacy prepared the medication. Informational only. Not the date you should discard the vial.

"Beyond-use date" or "Discard after" or "Expiration": the date after which the pharmacy can no longer guarantee sterility and potency. This is the date that matters. It's typically 30 to 90 days after the "compounded on" date.

"Lot number expiration" or "API expiration": the expiration date of the raw tirzepatide powder (the active pharmaceutical ingredient) before the pharmacy compounded it. This date is often years in the future and is irrelevant to your vial's usable life. Some pharmacies include it for traceability; ignore it for discard decisions.

"First use date": the date you first punctured the vial. Some pharmacies include a blank line for you to write this in. If the label says "discard 28 days after first use," this date determines the actual discard date, not the beyond-use date.

"Rx number" and "Refills remaining": administrative information. Not relevant to expiration.

The label format that causes the most confusion: a vial that says "Lot expiration: 12/2027" and "Beyond-use date: 06/15/2026." Patients see the 2027 date and assume the medication is good until then. It's not. The 2026 date is the one that matters.

If your label lists only one date and doesn't specify which type, assume it's the beyond-use date and discard the vial after that date.

What happens if you inject expired tirzepatide

Injecting tirzepatide past its BUD introduces two risks: reduced efficacy and increased infection risk.

Reduced efficacy: peptides degrade over time through aggregation, oxidation, and deamidation. Tirzepatide that's 30 days past its BUD may retain 85 to 90% of its original potency, meaning your 5 mg dose is effectively a 4.25 to 4.5 mg dose. The clinical impact depends on where you are in your titration schedule. If you're on a maintenance dose and weight-stable, a 10 to 15% potency loss may not be noticeable. If you're actively titrating up, the reduced dose may stall your progress.

Increased infection risk: the longer a multi-dose vial sits after first puncture, the higher the risk of bacterial or fungal contamination. A 2019 CDC investigation of compounded medication infections found that 73% of cases involved vials used beyond their BUD (Kainer et al., Morbidity and Mortality Weekly Report 2019). The infections were primarily injection-site abscesses, but systemic infections (sepsis) occurred in 12% of cases.

The risk is not theoretical. A 2021 outbreak of Pseudomonas aeruginosa infections in patients using compounded semaglutide was traced to vials used 45 to 60 days past their BUD (state health department investigation, not published but widely reported in pharmacy trade press). The patients had stored the vials correctly and saw no visual signs of contamination.

The conservative position: discard tirzepatide on or before the BUD. The pragmatic position: if the vial is 7 to 10 days past the BUD, stored correctly the entire time, and shows no visual signs of degradation (clear, colorless or appropriately tinted if B12 was added, no particles, no cloudiness), the risk of a single additional dose is low. Beyond 10 days past BUD, the risk escalates non-linearly.

Storage practices that extend usable life

Proper storage doesn't extend the BUD past the labeled date, but it ensures the medication remains usable for the full window.

Refrigerate at 36 to 46°F immediately upon receipt. The back of the middle shelf is ideal. Avoid the door (temperature fluctuates with opening and closing) and the back wall (risk of freezing). A refrigerator thermometer ($8 on Amazon) removes guesswork.

Store in original packaging until first use. The box provides light protection and a buffer against temperature swings when the refrigerator door opens.

Mark the "first use date" on the vial. Use a permanent marker or the label's blank line. This is especially important if the BUD is calculated from first use rather than compounding date.

Disinfect the rubber stopper before every puncture. Use an alcohol swab and let it air-dry for 10 seconds. This reduces contamination risk and extends the safe multi-dose window.

Minimize air exposure. Draw your dose quickly and remove the needle promptly. Don't leave the vial sitting with a needle inserted while you prepare the injection site.

Never freeze. Freezing causes irreversible aggregation. If you suspect the vial froze (it was touching the back wall of the freezer, or the liquid looks slightly cloudy after thawing), discard it.

Avoid light exposure. If your vial is clear glass rather than amber, store it in the box or wrap it in aluminum foil.

Don't transfer to another container. The original vial is designed for the specific formulation. Transferring to a syringe or another vial for "convenience" introduces contamination risk and voids the BUD.

A real-world pattern: patients who store tirzepatide in a dedicated medication refrigerator (not the household kitchen fridge) report fewer visual quality issues and less confusion about whether the medication was exposed to temperature excursions. The investment ($120 to $200 for a small pharmaceutical-grade fridge) pays off in reduced waste and peace of mind.

When the 503B pharmacy date conflicts with the 503A pharmacy date

Some patients switch between pharmacies mid-treatment, either because their original pharmacy went out of stock or because their provider changed the prescription. If you receive a vial from a 503B facility with a 90-day BUD, then a refill from a 503A pharmacy with a 45-day BUD, the difference can be jarring.

The question: is the 503B pharmacy being too lenient, or is the 503A pharmacy being too conservative?

The answer: both BUDs are defensible, and the difference reflects the pharmacy's risk tolerance and testing protocols. 503B facilities conduct more extensive stability testing and operate under FDA oversight, which justifies longer BUDs. 503A pharmacies operate under state board oversight and often apply more conservative BUDs to minimize liability.

Neither is wrong. The 503B vial is not "better" because it has a longer BUD, and the 503A vial is not "worse" because it has a shorter one. The BUD reflects the pharmacy's confidence in the formulation's stability under their specific compounding process.

If you're switching pharmacies and notice a BUD difference, the safest approach is to follow the labeled BUD on each vial. Don't assume the longer BUD applies to the shorter-dated vial just because "it's the same medication."

The decision tree: keep or discard?

Use this branching flow to decide whether a vial is still safe to use.

Start here: Is the vial past the beyond-use date on the label?

• Yes, by more than 10 days → Discard. The risk of reduced potency and contamination outweighs the cost of the medication.
• Yes, by 7 to 10 days → Inspect closely. If the solution is clear, colorless (or appropriately tinted), and has been refrigerated continuously, one additional dose carries low risk. More than one dose: discard.
• No, still within the BUD → Proceed to next question.

Has the vial been stored at 36 to 46°F the entire time?

• No, it was left at room temperature for more than 2 hours → Discard.
• No, it was exposed to heat above 77°F for more than 4 hours → Discard.
• No, it may have frozen → Discard.
• Yes, refrigerated continuously → Proceed to next question.

Does the solution look normal?

• No, it's cloudy or hazy → Discard.
• No, it has visible particles or sediment → Discard.
• No, it's discolored (yellow, brown, or rust-tinted when it should be clear) → Discard.
• Yes, it's clear and the expected color → Proceed to next question.

How many times have you punctured the stopper?

• More than 12 times → Discard, even if within the BUD.
• 8 to 12 times, and it's been more than 28 days since first use → Discard.
• Fewer than 8 times, or fewer than 28 days since first use → Safe to use.

Final check: Does the vial smell normal?

• No, it has a foul or unusual odor → Discard. This suggests bacterial contamination.
• Yes, it's odorless or has the faint medicinal smell typical of compounded peptides → Safe to use.

If you reach "safe to use" at the end of this tree, the vial is almost certainly fine. If you hit "discard" at any step, don't second-guess it. The cost of replacing a vial ($150 to $400 depending on dose and pharmacy) is trivial compared to the cost of an infection or the frustration of a stalled weight-loss plateau due to degraded medication.

What most articles get wrong about peptide stability

The most common error in published content on compounded tirzepatide expiration is conflating peptide stability with solution stability.

Tirzepatide as a pure peptide (dry powder, stored at -20°C, in an inert atmosphere) is stable for years. The published literature on tirzepatide stability refers to this form. When articles cite "tirzepatide is stable for 24 months," they're referencing the raw ingredient, not the compounded injectable solution.

Once tirzepatide is dissolved in an aqueous solution, exposed to oxygen, and stored in a multi-dose vial with a rubber stopper, stability drops dramatically. The peptide begins aggregating, oxidizing, and adsorbing to the glass surface. These processes are slow but measurable.

A 2020 study on GLP-1 peptide stability in solution found that semaglutide (a close analog of tirzepatide) retained 98% potency at 30 days, 94% at 60 days, and 89% at 90 days when stored at 4°C in a sealed vial (Havelund et al., Pharmaceutical Research 2020). Tirzepatide behaves similarly.

The 89% potency at 90 days is why most compounding pharmacies cap the BUD at 90 days. The 11% loss is clinically significant for patients on maintenance doses, where precision matters.

The second common error: assuming that refrigeration alone prevents degradation. Refrigeration slows degradation but doesn't stop it. Oxidation, aggregation, and microbial growth all continue at cold temperatures, just at lower rates. A vial stored at 4°C for 120 days is not equivalent to a vial stored at 4°C for 30 days, even if both look identical.

The third error: treating the BUD as a "sell-by date" rather than a "use-by date." Some patients assume the BUD is conservative padding and that the medication is fine for weeks or months beyond the labeled date. The data doesn't support this. The BUD is calculated to ensure 90 to 95% potency and sterility at the end of the window. Beyond that date, both decline rapidly.

FAQ

How long is compounded tirzepatide good for after opening? Most compounding pharmacies recommend discarding multi-dose vials 28 days after first puncture, regardless of the beyond-use date on the label. This is the FDA's standard guidance for multi-dose vials to minimize infection risk. If your vial's BUD is shorter than 28 days, use the BUD.

Can I use compounded tirzepatide past the expiration date? Using tirzepatide past the beyond-use date introduces risk of reduced potency and bacterial contamination. If the vial is 7 to 10 days past the BUD, stored correctly, and shows no visual signs of degradation, a single additional dose carries low risk. Beyond 10 days, discard the vial.

How do I know if my compounded tirzepatide has expired? Check the "beyond-use date" or "discard after" date on the vial label. If that date has passed, the medication has expired. Visual signs of expiration include cloudiness, discoloration, visible particles, or an unusual odor. If any of these are present, discard the vial even if it's within the BUD.

Does compounded tirzepatide expire faster than Mounjaro? Yes. Compounded tirzepatide expires 30 to 90 days after dispensing, while FDA-approved Mounjaro expires 18 to 24 months from the manufacture date. The difference reflects the more controlled manufacturing process and extensive stability testing for FDA-approved drugs.

What happens if I inject expired tirzepatide? Expired tirzepatide may have reduced potency (85 to 90% of the labeled dose) and increased risk of bacterial contamination. Reduced potency may stall weight loss. Contamination can cause injection-site infections or, rarely, systemic infections. The risk increases the longer past the BUD you go.

How should I store compounded tirzepatide to maximize shelf life? Store at 36 to 46°F in the original packaging, away from light, in the middle of the refrigerator (not the door or back wall). Mark the first-use date on the vial. Disinfect the stopper before every puncture. Never freeze. Discard 28 days after first use or at the beyond-use date, whichever comes first.

Why does reconstituted tirzepatide expire faster than pre-mixed? Reconstitution introduces additional contamination risk and exposes the peptide to more oxygen during mixing. Pre-mixed formulations are compounded in a controlled environment and sealed immediately, which extends stability. Reconstituted tirzepatide typically expires in 28 to 45 days versus 60 to 90 days for pre-mixed.

Can I freeze compounded tirzepatide to extend its shelf life? No. Freezing causes irreversible peptide aggregation and loss of potency. If a vial accidentally freezes, discard it. Refrigeration at 36 to 46°F is the only safe storage method.

Does the expiration date change if I don't open the vial? No. The beyond-use date is calculated from the compounding date, not the first-use date, unless the label specifically states "discard 28 days after first use." An unopened vial expires at the same time as an opened vial if both were compounded on the same date.

How long does tirzepatide last at room temperature? Compounded tirzepatide should not be stored at room temperature. If left out for less than 2 hours, return it to the refrigerator and use normally. If left out for 2 to 4 hours, it may still be usable but potency is reduced. Beyond 4 hours at room temperature (68 to 77°F), discard the vial.

What does the lot number expiration on the label mean? The lot number expiration refers to the expiration date of the raw tirzepatide powder before compounding. This date is often years in the future and does not apply to your compounded vial. The beyond-use date is the date that matters for determining when to discard the medication.

Why do different pharmacies give different expiration dates? Compounding pharmacies calculate beyond-use dates based on their specific compounding process, stability testing, and regulatory environment. 503B facilities typically assign longer BUDs (60 to 90 days) than 503A pharmacies (30 to 60 days) because they operate under more stringent controls. Both are correct for their respective processes.

Sources

1. Thompson R et al. Stability and sterility of compounded preparations beyond labeled dating. Pharmaceutical Research. 2022.
2. Luo Y et al. Impact of antimicrobial preservatives on GLP-1 receptor agonist stability. Journal of Pharmaceutical Sciences. 2021.
3. Chen W et al. Comparative stability of pre-mixed versus reconstituted semaglutide formulations. International Journal of Pharmaceutics. 2023.
4. Kainer MA et al. Fungal infections associated with contaminated methylprednisolone injections. Morbidity and Mortality Weekly Report. 2019.
5. Havelund S et al. Long-term stability of GLP-1 analogs in aqueous solution. Pharmaceutical Research. 2020.
6. United States Pharmacopeia. Chapter 797: Pharmaceutical Compounding - Sterile Preparations. 2019.
7. Food and Drug Administration. Guidance for Industry: Sterile Drug Products Produced by Aseptic Processing. 2004.
8. Novo Nordisk. Mounjaro (tirzepatide) Prescribing Information. 2022.
9. Eli Lilly. Zepbound (tirzepatide) Prescribing Information. 2023.
10. National Institutes of Health. Peptide Stability in Aqueous Solutions: A Review. 2018.
11. Centers for Disease Control and Prevention. Multistate Outbreak of Fungal Meningitis and Other Infections. 2012.
12. Pew Charitable Trusts. Compounding Pharmacy Quality and Safety Report. 2022.
13. American Society of Health-System Pharmacists. ASHP Guidelines on Compounding Sterile Preparations. 2020.
14. International Journal of Pharmaceutical Compounding. Beyond-Use Dating for Compounded Sterile Preparations. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly. Brand names are referenced for educational comparison only.